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Polycystic kidney diseases (PKD) are a group of inherited ciliopathies in which
the formation and growth of multiple cysts derived from the distal nephron and
collecting duct leads to the disruption of normal kidney architecture, chronic interstitial
inflammation/fibrosis and hypertension. Kidney failure is the most life-threatening
complication of PKD, and is the consequence of cyst expansion, renal interstitial disease
and loss of normal kidney tissue. Over the last decade, accumulating evidence suggests
that the autocrine and paracrine effects of ATP (through its receptor family P2X and
P2Y), could be detrimental for the progression of PKD. (2009). In vitro, ATP-P2 signaling
promotes cystic epithelial cell proliferation, chloride-driven fluid secretion and apoptosis.
Furthermore, dysfunction of the polycystin signal transduction pathways promotes the
secretagogue activity of extracellular ATP by activating a calcium-activated chloride channel
via purinergic receptors. Finally, ATP is a danger signal and could potentially contribute to
interstitial inflammation associated with PKD. These data suggest that ATP-P2 signaling
worsens the progression of cyst enlargement and interstitial inflammation in PKD.
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INTRODUCTION
Polycystic kidney diseases (PKD) are a group of inherited
ciliopathies in which the formation and growth of multiple
fluid-filled renal cysts leads to disruption of normal kidney archi-
tecture, chronic renal interstitial inflammation and fibrosis, and
hypertension (Harris and Torres, 2009). Kidney failure is the most
serious and life-threatening complication of PKD (Rangan et al.,
2005), and is the consequence of cyst expansion, renal intersti-
tial disease and loss of normal kidney tissue (Grantham et al.,
2011). Cyst growth in PKD is due to a combination of prolif-
eration of cyst-lining epithelial cells of the distal nephron and
collecting ducts, chloride-driven fluid secretion and extracellu-
lar matrix defects (Grantham et al., 1989). Although there is no
treatment to currently prevent kidney failure due to PKD, rapid
progress is being made (Harris and Torres, 2009). For example,
in 2012, a 3-year Phase 3 clinical trial using a small molecule
inhibitor (tolvaptan, a vasopressin type 2 receptor antagonist)
successfully attenuated the rate of kidney enlargement in humans
with PKD (Kelsey, 2013). The premise for the use of vasopressin
receptor antagonism was based on preclinical data showing that
vasopressin altered in intracellular purinergic (cAMP) signaling
in PKD (Wang et al., 2005).
It has been hypothesized that a multi-drug approach, targeting
cyst growth and interstitial inflammation, will be needed to effec-
tively prevent kidney failure in PKD (Aguiari et al., 2013), and
therefore further therapies are needed (Chang and Ong, 2013).
For over a decade, it has been postulated that the autocrine and
paracrine effects of extracellular nucleotides and their metabolites
could be detrimental for the progression of PKD, and that strate-
gies to attenuate this activation using inhibitors of nucleotide
release, nucleotide scavengers or nucleotide antagonists could be
useful for the therapy of PKD (Wilson et al., 1999; Schwiebert,
2001; Leipziger, 2003; Hillman et al., 2005; Hovater et al., 2008;
Xu et al., 2009). Currently, knowledge regarding the role of extra-
cellular nucleotides in the pathogenesis of kidney failure due to
PKD remains in the early phase of clinical translation. This is
highlighted by the paucity of published articles, as a PubMed
search performed on the 29th April 2013, using the terms “ATP
and polycystic kidney disease,” revealed 42 publications, only 15
of which were original scientific articles and 6 were review articles
that were directly relevant to this field of research. Nevertheless,
significant insights have been gained from this limited informa-
tion to support that extracellular nucleotide signaling is worthy
of further pursuit in PKD. In fact, it has been hypothesized that
this approach might act synergistically with vasopressin recep-
tor antagonism (Buchholz et al., 2011; Luft, 2011). Extracellular
nucleotides andmetabolites can be classified according to the base
from which they are derived and the number of associated num-
ber of phosphate groups (adenosine-derived; ATP, ADP; AMP;
guanosine-derived: GTP, GDP, GMP; cytidine-derived: CTP, CDP,
CMP; 5-methyluridine- and uridine-derived). Themajority of the
available data regarding extracellular nucleotides in PKD is based
on ATP-P2 receptor signaling. Therefore, this mini-review will
focus primarily on the role of ATP and its P2 receptors, in the
pathogenesis and progression of cyst enlargement and interstitial
inflammation in PKD.
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OVERVIEW OF PKD
PKD consists of several variants which differ according to their
mode of inheritance, underlying genetic mutation and pattern
of cyst formation. These variants include automosal dominant
PKD (ADPKD), autosomal recessive PKD (ARPKD) and other
autosomal recessive cystic renal diseases, including nephronoph-
thisis (NPHP). ADPKD is the most common type of cystic renal
disease, with an incidence of approximately one in every 1000
live births, and estimated to affect 6.5 million people world-wide
(Bisceglia et al., 2006; Harris and Torres, 2009). Structurally, in
ADPKD, the cysts are spherical in shape and occur in both kid-
neys. Cyst growth is not synchronized. Therefore the end-stage
kidney in ADPKD contains thousands of cysts that vary in size
from 100µm to several centimeters in diameter, resulting in a
large (weighing up to 3–5 kg, compared to 125–170 g in nor-
mal males) and irregularly shaped organ. In ADPKD, the cysts
start to form in early life (possibly in utero or during the early
postnatal period) due to the clonal proliferation of focal epithe-
lial cells lining the distal nephron and collecting duct, which
leads to diverticular-like protrusions extending into interstitium
(Baert, 1978). With continued growth, the latter detach from the
parent nephron when their diameter exceeds 100µm, and form
“encapsulated cysts” (Hovater et al., 2008). Once in the inter-
stitium the cysts continue to slowly expand over many decades
(Grantham et al., 2011). Kidney failure therefore occurs after a
long latent period, usually by the 5th decade of life (Baert, 1978),
when a sufficient number of cysts (possibly > 1000) (Luft, 2011)
have collectively grown to disrupt normal kidney architecture and
function. In contrast, ARPKD is a less frequent, childhood disease
(1:20 000 live births) (Sweeney and Avner, 2006). It is char-
acterized by the synchronized microcystic dilation of collecting
ducts. Detachment of the dilated cystic collecting ducts from the
nephron does not occur (Baxter, 1961). The kidneys are large but
maintain their reniform shape, and kidney failure typically occurs
during the neonatal period (Sweeney and Avner, 2006). NPHP
has an autosomal recessive mode of inheritance, and is charac-
terized by tubulointerstitial nephropathy and corticomedullary
duct ectasia, but kidney enlargement does not occur (Wolf and
Hildebrandt, 2011). NPHP is one of the most frequent genetic
disorders causing kidney failure in children and adolescents (Wolf
and Hildebrandt, 2011).
ADPKD, ARPKD and NPHP are caused by mutations in the
Pkd1/Pkd2, Pkhd1 andNphp (Grantham et al., 1989, 2011; Wilson
et al., 1999; Schwiebert, 2001; Rangan et al., 2005; Wang et al.,
2005; Harris and Torres, 2009; Xu et al., 2009; Aguiari et al.,
2013; Chang and Ong, 2013; Kelsey, 2013) genes respectively,
which encode the proteins, polycystin (PC)-1/PC-2, fibrocystin
and nephrocystin (Sweeney and Avner, 2006; Harris and Torres,
2009). These so-called “cystproteins” (Hildebrandt and Otto,
2005) have all been found to co-localize to the primary renal cilia
(an antenna-like sensory organelle involved in mechanosensa-
tion), and interact with each other at a molecular and functional
level (Kaimori and Germino, 2008; Fedeles et al., 2011). In phys-
iological states, the intact cystoprotein complex maintains the
normal function of the cilium, negatively regulates the cell-cycle
(Bhunia et al., 2002) and promotes intracellular calcium trans-
port (Cowley, 2008) and cellular differentiation as well as normal
renal tubular morphogenesis (Boletta and Germino, 2003). The
intracellular level of PC-1 plays a central role in both ADPKD and
ARPKD, as it is the rate-limiting component that ultimately deter-
mines cyst formation (Fedeles et al., 2011). Interestingly, ADPKD
is a focal disease, as only 1–2% of nephrons in a kidney develop
cysts (Martinez and Grantham, 1995). It has therefore been pos-
tulated that a heterozygote germ-line mutation in Pkd1 or Pkd2,
combined with postnatal disruption of the second normal allele
is required for cyst formation (the two-hit mechanism of the
Knudson theory) (Nauli et al., 2006). An additional molecular
explanation for the postnatal onset of ADPKD is an age-related
decline in the dosage of functional PC-1 protein (Rossetti et al.,
2009). In contrast to ADPKD, postnatal somatic mutations do
not have a role in cyst formation in ARPKD (Sweeney and Avner,
2006). Despite their importance in PKD, therapeutic approaches
to modulate the genetic expression of PCs has been problem-
atic because: (1) there is significant heterogeneity in the genetic
mutations of PC-1 (Harris and Torres, 2009); (2) over- as well
as under-expression of PC-1 can cause PKD (Harris and Torres,
2009); (3) there are difficulties with the delivery of viral vectors for
gene therapy due to the poor endocytosis capability of the epithe-
lial cells lining cysts (Witzgall et al., 2002). Therefore, treatments
to prevent kidney failure due to PKD have focused on the abnor-
malities in cellular function and signal transduction arising from
the dysfunction of cystproteins (Torres et al., 2007). These abnor-
malities are largely a consequence of reduced intracellular calcium
which leads to increased intracellular levels of cAMP. As discussed
earlier, cAMP levels are also increased by circulating vasopressin.
Halting the growth of cysts is one of themain therapeutic goals
in preventing the decline of kidney function in PKD. The mech-
anisms of cyst growth involve three factors (Torres et al., 2007;
Terryn et al., 2011): (i) increased proliferation of CECs: (ii) the
gradual and incremental accumulation of fluid inside cysts; and
(iii) abnormalities in extracellular matrix formation and degrada-
tion which are permissive for cyst expansion. The accumulation
of fluid in cysts is an important mechanism of disease progression
in PKD, and as discussed below, may be induced by purinergic
signaling (Terryn et al., 2011). It is due to the net transepithe-
lial secretion of chloride across apical membranes of CECs via
chloride channels [cystic fibrosis transmembrane conductance
regulator in response to the induction of cAMP-mediated protein
kinase A (CFTR-PKA); and calcium-activated chloride channels].
This chloride efflux then induces Na+ (as a result electric cou-
pling) and water (as a result of osmotic coupling via aquaporin
channels) efflux, resulting in the progressive accumulation of
fluid within the cysts (Terryn et al., 2011).
POTENTIAL MECHANISMS OF EXTRACELLULAR ATP
RELEASE AND P2 RECEPTOR SIGNALING IN PKD
The intracellular concentration of ATP ranges between 1 to
10mM (Beis and Newsholme, 1975), and ∼0.1% of this reser-
voir (Schwiebert, 2001) may theoretically be released into the
extracellular space (up to 10µmol/L) of the renal microenvi-
ronment in PKD, which includes the interior of encapsulated
cysts (as in ADPKD) (Schwiebert, 2001), the renal intersti-
tial space and/or the nephron lumen. The mechanisms of the
extracellular release could hypothetically involve (Jacobson and
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Boeynaems, 2010): (1) apoptosis and necrosis of cystic epithe-
lial cells (CECs) as well as destruction of normal renal epithelial
cells with disease progression (Goilav, 2011); (2) non-lytic mech-
anisms (Bowler et al., 2001) involving CECs, that requires the exo-
cytosis of secretary granules, vesicular transport and membrane
channels and include ATP-binding cassette transporters, pannex-
ins and connexins (Lohman et al., 2012), possibly in response to
mechanical stretch [as shown in bladder epithelial cells (Ferguson
et al., 1997)], hypoxia (Bergfeld and Forrester, 1992), dysfunc-
tion of cystoproteins (Schwiebert et al., 2002), increased cellular
metabolism (Wilson, 1997; Sullivan et al., 1998) and other ATP
release mechanisms that may be abnormal in PKD (Schwiebert
et al., 2002); and (3) release of ATP from other local sources such
as infiltrating inflammatory cells and renal nerves (Bailey et al.,
2000).
Once in the extracellular fluid, ATP is capable of activating
purinergic receptors, which are one of the most abundant recep-
tor families inmammalian tissues (Abbracchio et al., 2009). There
are two groups of ATP-responsive (P2) receptors: (i) P2Y recep-
tors are G-protein coupled which act through a secondmessenger,
and respond to a wide variety of nucleotides (ATP, ADP, UTP,
UDP and UDP-glucose) They consist of eight members (subtypes
1, 2, 4, 6, 11, 12, 13, and 14, which vary depending on the type
of G protein involved and specificity of the ligand) (Jacobson
and Boeynaems, 2010) and modulate intracellular calcium and
cAMP; and (ii) P2X receptors are rapidly acting non-selective
cation channels that are calcium permeable, and which open pri-
marily after binding to ATP (Schwiebert, 2001). They consist of
eight subtypes, and in response to ATP-ligand binding, cause
plasma membrane depolarization which allows calcium influx
from external stores (Schwiebert, 2001).
Extracellular ATP is rapidly degraded in the plasma (Gorman
et al., 2007) and in order for it to have a physiological or patholog-
ical function, it requires accumulation in the local microenviron-
ment. The net build-up of ATP in PKD is likely to be dependent
on a number of factors (Di Virgilio, 2012): (i) the pattern of P2
receptor expression in cystic and non-cystic renal tissue as well
as in infiltrating inflammatory cells; (ii) the level of expression of
nucleotide hydrolyzing enzymes (CD39 and CD73), which break-
down ATP and generate adenosine, which has anti-inflammatory
and anti-tumor effects (Di Virgilio, 2012).
EVIDENCE FOR ATP RELEASE INTO THE LOCAL
MICROENVIRONMENT AND P2 RECEPTOR ALTERATION IN
PKD
Fluid extracted frommicro-dissected cysts from ADPKD patients
was found to contain pharmacologically relevant levels of ATP
(up to 10µM) (Wilson et al., 1999), which is a thousand times
higher than that found in peripheral blood (Lazarowski et al.,
2001). Primary cultures of renal epithelial cells from ADPKD and
ARPKDpatients release between two to five times more ATP, both
across the apical and basolateral membrane, under resting condi-
tions and with hypotonic challenge, compared to non-ADPKD
cells (Wilson et al., 1999; Schwiebert et al., 2002). This might, in
part, be due to the slower degradation of ATP in ADPKD cells
due to a reduced expression of CD39 (Xu et al., 2009) or other
mechanisms. ATP, in concentrations of 4 nM, was also detectable
in cyst fluid from cpk mice (a murine model that phenotypically
resembles ARPKD, and is due to a mutation in cystin) (Hillman
et al., 2004). However, the presence of ATP in the interstitial
space, nephron lumen or urine of patients and animals with PKD
has not been reported and is not known. In the microenviron-
ment of tumors (which are thought to share some analogy to the
pathogenesis of PKD) (Ghiringhelli et al., 2009), ATP has been
shown to accumulate, and under these circumstances, thought to
be primarily due to increased cancer cell metabolism and tumor-
associated inflammation (Ghiringhelli et al., 2009; Di Virgilio,
2012). This could potentially also be the case in PKD.
Several studies have examined the expression of P2 receptors
in vitro and in vivo in the cyst lining epithelium in PKD. In pri-
mary cultures of ADPKD and ARPKD cells from humans, mRNA
for both P2X and P2Y receptors was found to be expressed (Xu
et al., 2009). In cpk mice, immunohistology showed that collect-
ing duct cysts were positive for P2X7 protein (Hillman et al.,
2002). Similarly, in human ARPKD, P2X7 was also expressed in
the epithelial cells of dilated collecting ducts and cysts but not
present in normal human fetal kidneys (Hillman et al., 2004).
In the Han:Sprd rat model of PKD, CECs from heterozygous
rats were positive for P2Y (Y2 and Y6), P2X5 and P2X7 (Turner
et al., 2004). Taken together, these data suggest that ATP accumu-
lates in the PKD microenvironment, and that CECs possess the
appropriate receptors to be able to respond to the presence of the
ligand.
CILIARY DYSFUNCTION IN PKD ALTERS THE AUTOCRINE
ATP-P2 AXIS, INTRACELLULAR CALCIUM AND CHLORIDE
SECRETION IN CYSTIC EPITHELIAL CELLS
Growing evidence suggests that extracellular ATP has a phys-
iological role in maintaining the health and function of renal
epithelial cells, and that this is dependent on an intact and func-
tioning cilium. In immortalized normal human kidney tubular
epithelial cells (HK-2 cell line), P2X7 receptors were localized to
the primary cilia, supporting the possibility that ATP-P2 signal-
ing is involved in mechanosensation and cyst formation (Chang
and Ong, 2013). In addition, in C. Elegans, ATP synthase (which
produces ATP from ADP) physically associates with the poly-
cystins, LOV-1 and PKD2, suggesting that ATP synthase activity
could be dysfunctional in PKD andmight be a factor contributing
to extracellular accumulation of ATP (Hu and Barr, 2005). The
importance of a functioning cilia for ATP-purinergic signaling
was further revealed from in vitro studies of collecting duct prin-
cipal cells from Oak Ridge Polycystic kidney disease (orpktg737)
mice [a model of ARPKD in which cells lack a cilium due to a
mutation in polaris (Hovater et al., 2008)]. These studies showed
that the complete absence of an apical cilia impairs ATP secre-
tion in response to mechanical, chemical and osmotic stimuli, in
collecting duct principal cells (Hovater et al., 2008).
In normal renal epithelial cells extracellular ATP promotes
chloride secretion and regulates intracellular calcium (Wildman
et al., 2003). In PKD mutant cells, accumulating evidence sug-
gests that chloride secretion in response to ATP is exacerbated. For
example, over-expression of the cytoplasmic COOH-terminus of
PC-1 in mouse cortical collecting duct cells prolonged the dura-
tion of chloride conductance in response to ATP, supporting
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the hypothesis that PKD mutant cells are more sensitive to
some of the physiological effects of ATP (Hooper et al., 2003;
Wildman et al., 2003). Therefore, it has been hypothesized that
the dysfunction of the PC signal transduction pathways promotes
the “secretagogue activity” of extracellular ATP by stimulating
a calcium-activated chloride channel via purinergic receptors
(Hooper et al., 2003; Wildman et al., 2003). In addition to
chloride, ATP also acts in an autocrine fashion to stimulate intra-
cellular calcium via purinergic receptor signaling. However, the
intracellular calcium response to ATP is impaired in both murine
and human ADPKD cells (Hovater et al., 2008; Xu et al., 2009).
The latter was also associated with a reduced expression P2X7 and
CD39 (Xu et al., 2009).
FUNCTIONAL EVIDENCE SUGGESTING THAT
EXTRACELLULAR ATP-P2 SIGNALING DIRECTLY PROMOTES
CYST EXPANSION AND INTERSTITIAL INFLAMMATION IN
PKD
CYST EXPANSION (CHLORIDE-DRIVEN FLUID SECRETION AND
PROLIFERATION OF CECs)
In normal inner medullary collecting duct cells extracellular
purinergic agonists can bemitogenic or co-stimulatory with other
growth factors (Ishikawa et al., 1997). Therefore, in PKD, ATP
has been postulated to have a role in the expansion of encapsu-
lated renal cysts (as in ADPKD) or cystic tubular expansion (as
in the ARPKD). It has been suggested that because cysts in the
former are “encapsulated,” ATP accumulation may have a more
important pathogenic role because of sequestration within the
cyst interior, but this has not been proven (Schwiebert, 2001).
To date the functional roles of ATP-P2 signaling on the mech-
anisms of cyst expansion has been examined in vitro in cultured
cells and in a zebrafish model. Collectively, these studies have
indicated that ATP-P2 signaling may either accelerate or attenu-
ate cyst growth. Similar to normal tubular epithelial cells (Kishore
et al., 1995, 2000), in primary cultures of human PKD cells,
ATP agonists (ATP, Bz-ATP and UTP) increased intracellular cal-
cium levels and secretory anion transport by activating chloride-
dependent secretion (that was independent of cAMP/PKA/CFTR)
(Schwiebert et al., 2002). In contrast, Hillman and colleagues
examined the role of ATP-P2 signaling in the initial steps of cyst
formation, by growing CEC aggregates ex vivo from cpk mice
(Hillman et al., 2004). In this study, the exposure of these cells
to 2′- and 3′-O-(4-benzoylbenozoyl)-adensosine 5′-triphosphate
(BzATP, a P2X7 agonist) reduced the number of cysts that formed
by approximately one-third (Hillman et al., 2004). Cyst size and
proliferation was not altered but there was a non-significant
increase in caspase-3 activity (Lazarowski et al., 2001). Exogenous
ATP and UTP also reduced cyst number in this model but to
a much lesser extent (nearly 10%) (Lazarowski et al., 2001).
In comparison to cpk mice CECs, in MDCK cell-derived cysts,
treatment with non-specific P2 receptor antagonists (Reactive
Blue 2, suramin) or removal of ATP from culture medium with
apyrase (by 50%) attenuated the cAMP-ERK-dependant growth
by ∼50% (Turner et al., 2007). In this model, cyst growth was
not affected by treatment with a non-selective P2X inhibitor,
Coomassie Brilliant Blue G), suggesting a role for P2Y receptors
(Turner et al., 2007). Similarly, in a separate report, in MDCK
cysts derived from principal cells (Clone C7), ATP-dependent cyst
growth was driven by fluid secretion rather than cell prolifera-
tion and was synergistic with cAMP (Buchholz et al., 2011). The
latter was largely dependent on extracellular ATP and attenuated
by the P2 receptor antagonist, suramin (Buchholz et al., 2011),
and the effects were not evident in MDCK cells derived from
intercalated cells (Buchholz et al., 2011). Consistent with the data
in MDCK cells, in a zebrafish model of ADPKD (morpholino
induced knockdown of Pkd2), a P2X7 antagonist (oxidized ATP)
markedly reduced the cystic dilatation and peritubular oedema in
pronephric ducts compared to the control (no treatment) or to a
P2X7 agonist (Bz-ATP) (Chang et al., 2011). This was associated
with a reduction in cell proliferation and p-ERK activity (Chang
et al., 2011).
The contrasting results mentioned above are most likely due
to differences in the experimental design (particularly the stage of
cyst growth), the cellular model and the type of PKD examined.
Perhaps, ATP-P2 signaling reduces cyst formation (as in cpk CEC
aggregates) but promotes expansion once the cysts have actually
formed. Further in vivo data using genetically orthologous models
of PKD are awaiting to provide clarification regarding the role of
ATP-P2 signaling in initiation and growth of cysts in PKD.
RENAL INTERSTITIAL INFLAMMATION
Renal interstitial inflammation is recognized as an important fac-
tor in the progression in PKD (Ta et al., 2013). Macrophage accu-
mulationmay promote cyst growth and interstitial inflammation,
and be detrimental to the progression of PKD (Swenson-Fields
et al., 2013; Ta et al., 2013). The release of excess extracellu-
lar ATP is a “danger signal” that is likely to lead to interstitial
inflammation via inflammatory signaling pathways (Idzko et al.,
2007; Ivison et al., 2011). To date, the role of ATP-P2 signal-
ing in mediating interstitial inflammation associated with PKD
has not been examined. Based on data from other experimental
models, one might hypothesize that extracellular ATP (released
into the renal interstitium by inflammatory cells and CECs)
could have a proinflammatory effect (Deplano et al., 2013). For
example, in antibody-mediated autoimmune glomerulonephri-
tis, renal injury, glomerular macrophage accumulation and the
urinary excretion of the monocyte chemoattractant protein-1
was attenuated by P2X7 deficiency (in mice) or by administra-
tion of a P2X7 antagonist (A-438079) (in rats) (Taylor et al.,
2009) Similarly, in a murine model of renal interstitial fibro-
sis (unilateral ureteral obstruction), interstitial macrophage and
myofibroblast accumulation, interstitial fibrosis and tubular cell
apoptosis was also attenuated by P2X7 deficiency (Goncalves
et al., 2006). Lastly, preliminary data shows that treatment of
rats with unilateral ureteral obstruction with a P2X7 antagonist
(Brilliant Blue G) also attenuated interstitial inflammation and
fibrosis but increased tubule cell proliferation (Leite et al., 2012).
The latter raises the possibility that the ATP-P2 system could have
complex and divergent effects in vivo in PKD.
FUTURE DIRECTIONS AND POTENTIAL FOR ATP-P2
SIGNALING IN THE THERAPY OF HUMAN PKD
Clinical trials (Phase 1 and 2) to determine the safety and
efficacy of P2X7 receptor antagonists in chronic inflammatory
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diseases (rheumatoid arthritis, inflammatory bowel disease) are
presently in progress [reviewed in Arulkumaran et al. (2011)]. In
PKD, further preclinical evidence is required before clinical tri-
als of P2X7 receptor antagonists can be considered. Experiments
comparing disease progression in compound/double knock-
out mice using P2X−/−7 mice and genetically orthologous/non-
orthologous murine models of PKD are required (Hillman et al.,
2005). In addition, in experimental models of cancer, the over-
expression of either CD39 or CD73 promotes tumor progression
due to loss of tumor-associated inflammation (Synnestvedt et al.,
2002; Eltzschig et al., 2009). On the other hand, in PKD, the loss
of interstitial inflammation due to the transgenic expression of
CD39 or CD73, might be renoprotective, as shown in experi-
mental renal ischaemia (Crikis et al., 2010). Studies to determine
the effects small molecule inhibitors (such as Brilliant Blue G,
suramin, A-438079 or preferably those used in clinical trials)
during the early as well as the established phases of PKD in
small animal models are also needed. In particular, the stage-
and disease-specific effects (relevant to human disease) of ATP-
purinergic signaling in preclinical models needs to be understood
(Schwiebert et al., 2002). The effects of natural and existing small
molecule modulators of ATP-P2 signaling in the pathogenesis of
PKD should not be forgotten, as this may accelerate translation
to the clinic. For example, the methylxanthine, caffeine, induced
ATP release in smooth muscle cells (Katsuragi et al., 2008), and
it is possible that effects on P2 receptors underlie its ability to
promote chloride driven fluid secretion in human ADPKD cells
(Belibi et al., 2002). Similarly, the effects of existing pharma-
cological inhibitors, such as clopidogrel and ticlopidine which
affect P2Y12 receptors (Savi and Herbert, 2005), on cyst growth
in in vitro models, could be screened.
CONCLUSION
Evidence accumulated to date supports that ATP-P2 signaling is
potentially important in the pathogenesis of PKD. However, the
study of ATP-P2 signaling in PKD is presently in an early phase of
investigation (Figure 1) and further work, particularly preclinical
FIGURE 1 | Hypothetical diagram showing the potential role of ATP-P2
signaling in the pathogenesis of cyst growth and interstitial
inflammation in PKD. Current data suggests that extracellular ATP is
increased in the microenvironment of the kidney affected by PKD, due to
apical/basolateral release by cystic epithelial cells. Reduced degradation or
increased cellular sensitivity to ATP may also contribute to net accumulation
of ATP in the local environment. The presence of extracellular ATP has
paracrine and autocrine effects on numerous cells, including cystic epithelial
cells and interstitial inflammatory cells. In cystic epithelial cells, in vitro data
suggests that P2 receptor activation promotes chloride-driven fluid secretion
(independent of PKA-cAMP-CFTR mechanism) and proliferation (via p-ERK),
both of which lead to cyst growth. In addition, preclinical data from non-PKD
animal models suggests that P2 signaling promotes the chemotaxis of
macrophages and lymphocytes, promoting interstitial inflammation. However,
the hierarchy by which ATP-P2 signaling mediates proliferation, chloride
secretion and interstitial inflammation in PKD is not known. In addition, the
localization of P2 receptors (basolateral vs. apical distribution) or whether
specific receptors have unique functions is not known.
in vivo studies, are needed before randomized controlled trials
using small molecular inhibitors of P2 receptor antagonists in
humans with PKD can be considered.
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